BTIG Remains a Buy on Arcutis Biotherapeutics (ARQT)
I'm PortAI, I can summarize articles.
BTIG analyst Kambiz Yazdi reiterated a Buy rating on Arcutis Biotherapeutics with a $31.00 price target. Yazdi, who covers the Healthcare sector, has a 48.4% average return and a 76.92% success rate on recommended stocks. The general analyst consensus for Arcutis Biotherapeutics is a Strong Buy with a $29.71 average price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments